Literature DB >> 33094568

Aggregation-Induced Emission Luminogens for Mitochondria-Targeted Cancer Therapy.

Yanyan Huang1,2, Guanxin Zhang1,2, Rui Zhao1,2, Deqing Zhang1,2.   

Abstract

The importance of mitochondria in tumorigenesis makes these organelles an ideal target for cancer therapy. In recent years, luminogens with the aggregation-induced emission (AIE) effect have been developed for mitochondrial targeting and cancer treatment. The induction of mitochondrial dysfunction can be an effective pathway of chemotherapy, photodynamic therapy, and combination therapy against cancer. This review focuses on recent progress in the field of AIE luminogens (AIEgens) for cancer theranostics based on mitochondrial targeting and dysfunction. AIEgens for cancer treatment, including chemotherapy, photodynamic therapy, and combination therapy, are summarized herein. Molecular design efforts toward mitochondrial targeting and mitochondria-damaging mechanisms are also discussed. Finally, we discuss the challenges and future directions of development for AIEgens in mitochondria-targeted cancer treatment.
© 2020 Wiley-VCH GmbH.

Entities:  

Keywords:  aggregation-induced emission; cancer; chemotherapy; mitochondria; photodynamic therapy

Year:  2020        PMID: 33094568     DOI: 10.1002/cmdc.202000632

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  2 in total

1.  Fighting metallodrug resistance through alteration of drug metabolism and blockage of autophagic flux by mitochondria-targeting AIEgens.

Authors:  Yan Su; Hai Lin; Ying Tu; Meng-Meng Wang; Guan-Dong Zhang; Jin Yang; Hong-Ke Liu; Zhi Su
Journal:  Chem Sci       Date:  2022-01-18       Impact factor: 9.825

2.  TME-targeting theranostic agent uses NIR tracking for tumor diagnosis and surgical resection and acts as chemotherapeutic showing enhanced efficiency and minimal toxicity.

Authors:  Zhongyuan Xu; Jianqiang Qian; Chi Meng; Yun Liu; Qian Ding; Hongmei Wu; Peng Li; Fansheng Ran; Gong-Qing Liu; Yunyun Wang; Yong Ling
Journal:  Theranostics       Date:  2022-02-28       Impact factor: 11.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.